Study on Determine the Utilisation and Clinical Outcomes of Evusheld in COVID-19 PrEP in China

Trial Identifier:	D8850R00019
Sponsor:	AstraZeneca
NCTID::	NCT05917951
Start Date:	December 2022
Primary Completion Date:	July 2023
Study Completion Date:	July 2023
Condition:	COVID-19 Immunisation

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
China, Hainan	Qionghai, Hainan, China

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.